国金证券给予华东医药买入评级：新产品拉动工业板块增长，研发布局不断丰富

Group 1 - The core viewpoint of the report is that Huadong Medicine (000963.SZ) is rated as a "buy" due to growth driven by new product launches in the industrial sector, despite short-term pressure on the medical beauty segment [2] - The report highlights that the innovation and research layout of the company is continuously enriching, with significant clinical progress in key products [2] Group 2 - The industrial sector is experiencing growth due to the release of new products, while the medical beauty sector is facing short-term challenges [2] - The company is making continuous advancements in its innovation and research efforts, which is expected to enhance its product offerings [2]